---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-100574"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-09-16T21:08:11+00:00"
generated_at: "2026-09-16T21:10:06.236850+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adial amends warrant deals to reclassify $22.7M liability to equity, regain Nasdaq compliance

## Summary
- On Sep 16, 2026, amended Purchase and Note Exchange Agreements to remove Penalty Provision, add lock-up on warrant shares.
- Milestone Warrant rights reclassified from liability to equity: $19.7M (PIPE) and $3.0M (noteholders) to additional paid-in capital.
- Pro forma equity improves from $(38.4M) deficit to $22.9M positive as of Jun 30, 2026.
- Series A Preferred (12,930.617 shares) converts to 12.93M common shares; total common shares pro forma 15.56M.
- Amendments intended to satisfy Nasdaq continued listing and initial listing standards for change of control at Sep 17 Annual Meeting.

## SEC filing metadata
- accession: 0001213900-26-100574
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-09-16T21:08:11+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026100574/0001213900-26-100574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026100574/ea0305675-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-100574
- JSON: https://secwatch.observer/filing/0001213900-26-100574.json
- Plain text: https://secwatch.observer/filing/0001213900-26-100574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.